• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Apollomics Inc.

    9/25/25 5:01:38 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLM alert in real time by email
    6-K 1 d58766d6k.htm FORM 6-K Form 6-K
    OMB APPROVAL
    OMB Number:   3235-0116
    Expires:   December 31, 2026
    Estimated average burden
    hours per response   8.7

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of September, 2025.

    Commission File Number 001-41670

     

     

    Apollomics, Inc.

    (Translation of registrant’s name into English)

     

     

    989 E. Hillsdale Blvd., Suite 220, Foster City, California 94404

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    ☒ Form 20-F    ☐ Form 40-F

     

     
     


    Press Releases

    On September 22, 2025, Apollomics Inc. (“Apollomics” or the “Company”) issued a press release announcing its receipt of a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that unless the Company requests an appeal, Nasdaq will delist the Company’s securities under Nasdaq Listing Rule 5101 based on the Staff’s belief that Apollomics is now only a “public shell”. As discussed in greater detail in the press release, the Company disagrees with the Staff and will appeal. The press release also provides certain updates with respect to the Company’s ongoing operations.

    On September 25, 2025, Apollomics issued another press release announcing its completion of the filing of its application on September 23, 2025 to appeal the delisting notification it had earlier received from the Staff of Nasdaq. Additionally, Apollomics announced that in connection with the Writ and Statement of Claim issued in the Grand Court of the Cayman Islands by one investment manager for two minority investors in the Company dated July 22, 2024 (the “Cayman Litigation”), the Grand Court of the Cayman Islands has issued a consent order via consent of all parties that all further steps in these proceedings of the Cayman Litigation are stayed from and after September 12, 2025, until further order from such court.

    The press releases are attached here as Exhibit 99.1 and 99.2.

    EXHIBITS

     

    Exhibit
    No.
      

    Description

    99.1    Press Release - Apollomics Announces Receipt of Delisting Determination Letter from Nasdaq
    99.2    Press Release - Apollomics Announces Completion of Filing of Appeal of Nasdaq Delisting Order


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

       

    /s/ Peter Lin

    Date September 25, 2025    
        (Signature)*
        Peter Lin, Chief Financial Officer
        * Print the name and title under the signature of the signing officer.

     

    SEC 1815 (07-22)    Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.
    Get the next $APLM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APLM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nasdaq Halts Apollomics Inc., Ltd.

    NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading was halted on September 17, 2025 in Apollomics Inc., Ltd. at 14:37:17 Eastern Time for additional information requested from the company. The last sale price of the company's ordinary shares was $18.4331 (NASDAQ:APLM), and warrants was $0.0191 (NASDAQ:APLMW). Trading will remain halted until Apollomics Inc. has fully satisfied Nasdaq's request for additional information. For news and additional information about the company, please contact the company directly or check under the company's symbol using InfoQuotesSM on the Nasdaq® Web site. For more information about The Nasdaq Stock

    9/17/25 5:48:56 PM ET
    $APLM
    $NDAQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

    Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi") to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for the vebreltinib development program, including in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification$9.8 million in cash and cash equivalents as of December 31, 2024, in conjunction with LaunXP upfront payment, pipeline focus and expense reductions expected to provide cash runway into the first quarter of 2026 FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics"), a late-stage clinical bio

    4/3/25 4:05:00 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

    LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer ("NSCLC")Apollomics to receive upfront payments of $10 million, and is eligible for pre-commercial milestones up to $50 million, and royalties on net product sales FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and LaunXP International Co.,

    3/31/25 8:00:32 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    SEC Filings

    View All

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    9/25/25 5:01:38 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    9/5/25 6:05:16 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    9/3/25 4:05:17 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Apollomics Inc.

    SC 13D/A - Apollomics Inc. (0001944885) (Subject)

    8/15/24 4:38:25 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Apollomics Inc. (Amendment)

    SC 13G/A - Apollomics Inc. (0001944885) (Subject)

    5/30/24 4:15:08 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Apollomics Inc. (Amendment)

    SC 13D/A - Apollomics Inc. (0001944885) (Subject)

    5/22/24 7:32:01 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Financials

    Live finance-specific insights

    View All

    Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

    Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-

    3/28/24 7:00:00 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

    FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets. Apollomics' management team will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The conference call will be available on Apollomics' website, www.apollomicsinc.com, under the Investors section and will be archived there for approximately 90 days. The co

    3/26/24 8:00:00 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

    Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash, cash equivalents, and investments at June 30, 2023; Cash runway to mid-year 2024 Debuted as a publicly traded targeted oncology company March 30, 2023 Management to host conference call Monday, October 2, 2023 at 8:30 a.m. ET FOSTER CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) (the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today annou

    9/28/23 4:17:57 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care